A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance

@article{Goldfine2012ART,
  title={A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance},
  author={Allison B Goldfine and Paul R. Conlin and Frank A Halperin and Juraj Koska and Paska A. Permana and Dawn C. Schwenke and Steven E. Shoelson and Peter D. Reaven},
  journal={Diabetologia},
  year={2012},
  volume={56},
  pages={714-723}
}
Aims/hypothesisChronic sub-acute inflammation contributes to the pathogenesis of type 2 diabetes mellitus and cardiovascular disease. High doses of salicylate reduce inflammation, glucose and triacylglycerols, and may improve insulin sensitivity, suggesting therapeutic potential in impaired fasting glucose and/or impaired glucose tolerance. This trial aimed to evaluate the effect of salsalate vs placebo on insulin resistance and glycaemia in impaired fasting glucose and/or impaired glucose… Expand

Paper Mentions

Interventional Clinical Trial
The hypothesis is that western lifestyle, with sedentary behaviors and caloric excess promote a chronic, subacute inflammatory state that participates in the development and progression… Expand
ConditionsCoronary Artery Disease, Overweight
InterventionDrug
Interventional Clinical Trial
Background: The prevalence of obesity has increased throughout the last three decades due to genetic, metabolic, behavioral, and environmental factors. Obesity and high-fat western… Expand
ConditionsDiabetes Risk
InterventionDrug
Effect of Salsalate on Insulin Action, Secretion, and Clearance in Nondiabetic, Insulin-Resistant Individuals: A Randomized, Placebo-Controlled Study
TLDR
Salsalate treatment in nondiabetic, insulin-resistant individuals improved fasting, but not postprandial, glucose and triglyceride concentration, and improvements were associated with a decrease in insulin clearance rate without change in insulin action or insulin secretion. Expand
Salsalate treatment for prediabetes: a therapeutic alternative?
  • S. Kim, G. Reaven
  • Medicine
  • Diabetic medicine : a journal of the British Diabetic Association
  • 2017
TLDR
An argument can be made that administration of salsalate may be of unique benefit to those who are overweight/obese and insulin-resistant before gross decompensation of glucose tolerance, but at increased risk of Type 2 diabetes and cardiovascular disease. Expand
Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individuals.
TLDR
Atherogenicity of the lipid, lipoprotein, and apoprotein profile of insulin-resistant individuals who were overweight or obese improved significantly in association with salsalate treatment. Expand
Salsalate has no effect on insulin secretion but decreases insulin clearance: a randomized, placebo‐controlled trial in subjects without diabetes
TLDR
Salsalate did not alter insulin secretion, but lowered MCI, indicating that a reduction in insulin clearance is the principal mechanism for increased insulin levels after salalate administration. Expand
Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD)
TLDR
This finding suggests that salsalate does not have an effect on vascular inflammation, inflammation does not cause endothelial dysfunction in T2D, or confounding effects of salsAlate mitigate favorable effects on endothelial function. Expand
Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins.
TLDR
Salsalate when added to current therapies that include a statin does not reduce progression of noncalcified coronary plaque volume assessed by multidetector computed tomographic angiography in statin-using patients with established, stable coronary heart disease. Expand
Treatment with high dose salicylates improves cardiometabolic parameters: Meta-analysis of randomized controlled trials.
TLDR
High dose salicylates appear to improve cardiometabolic risk factors in healthy individuals and type 2 diabetes patients and following withdrawal due to adverse events. Expand
The Effect of Salsalate Therapy on Endothelial Function in a Broad Range of Subjects
TLDR
Salsalate therapy, particularly when therapeutic salicylate levels are achieved, impairs endothelium‐dependent vasodilation in a broad range of subjects, raising concern about the possible deleterious effects of anti‐inflammatory doses of salsalates on cardiovascular risk. Expand
Inflammation in the pathophysiology and therapy of cardiometabolic disease.
TLDR
There is a great need for comprehensive and well-designed clinical studies to implement anti-inflammatory drugs in the treatment of patients with metabolic syndrome and its associated conditions. Expand
A possible Role of Salicylates in Diabetes Type II
TLDR
The responsibility of inflammation in insulin resistance and the role of aspirin as antiplatelets and antidiabetic drug are summarized. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study
TLDR
The glucose-lowering potential of salicylates appears to be due to effects on insulin concentration rather than improved insulin action, which may be useful for the treatment and prevention of type 2 diabetes. Expand
Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes.
TLDR
Treatment with salsalate can reduce insulin resistance and the FPG level in subjects with prediabetes and determination of the long-term safety and efficacy of the use of salalate necessitates further investigation. Expand
Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes
TLDR
The results show that salsalate is effective in improving glycemic control in newly diagnosed naïve patients with T2DM and the optimal duration of treatment and sustainability of its effect requires further study. Expand
The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes
TLDR
The number of patients studied and the trial duration were insufficient to warrant recommending the use of salsalate for type 2 diabetes at this time, but the drug was otherwise well tolerated. Expand
Prolonged fasting induces peripheral insulin resistance, which is not ameliorated by high-dose salicylate.
TLDR
Prolonged fasting induces profound peripheral IR, in contrast to type 2 diabetes mellitus, high-dose salicylate does not affect fasting-induced peripheral IR. Expand
Acetylsalicylic acid improves lipid-induced insulin resistance in healthy men.
TLDR
ASA pretreatment attenuated lipid-induced insulin resistance in healthy humans, and the acute insulin-sensitizing effect of ASA was unrelated to changes of circulating inflammatory markers. Expand
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.
TLDR
The hypothesis that IKKbeta represents a new target for treating type 2 diabetes mellitus is supported. Expand
Salicylates increase insulin secretion in healthy obese subjects.
TLDR
The administration of a salicylate compound led to lowering of serum glucose concentration in subjects with normal glucose tolerance or type 2 diabetes, and it is suggested that this effect was mediated through increased insulin secretion induced by salingylate directly on the beta-cell. Expand
Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes
TLDR
Exenatide ameliorates postprandial endothelial dysfunction after a high-fat meal and is inversely associated with mean postpr andial concentrations of triglycerides. Expand
Aspirin causes tissue insensitivity to insulin in normal man.
TLDR
It is demonstrated that aspirin not only enhances beta-cell sensitivity to glucose, but also impairs glucose metabolism in insulin-sensitive tissues. Expand
...
1
2
3
4
5
...